[{"id":"7026c02a-02d2-4eaf-9842-da3071018ea9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02443077","created_at":"2021-01-18T11:42:20.749Z","updated_at":"2024-07-02T16:34:37.048Z","phase":"Phase 3","brief_title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT02443077","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2 • BCL6 • TNFA • CARD11 • TNFAIP3 • CD79A • GSTT1","pipe":" | ","alterations":" CD79A mutation + CD79B mutation","tags":["MYC • BCL2 • BCL6 • TNFA • CARD11 • TNFAIP3 • CD79A • GSTT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79A mutation + CD79B mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 302","initiation":"Initiation: 10/12/2016","start_date":" 10/12/2016","primary_txt":" Primary completion: 05/10/2025","primary_completion_date":" 05/10/2025","study_txt":" Completion: 05/10/2025","study_completion_date":" 05/10/2025","last_update_posted":"2024-06-07"},{"id":"a86fead0-6d68-4e5e-8342-7224d15b5ca0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04994626","created_at":"2021-08-06T12:53:05.326Z","updated_at":"2024-07-02T16:36:26.846Z","phase":"Phase 2","brief_title":"Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies","source_id_and_acronym":"NCT04994626","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" CD20 • MYD88 • CD79B • CD79A","pipe":" | ","alterations":" CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation","tags":["CD20 • MYD88 • CD79B • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2021-08-06"}]